News

A view of highlights and trends from the September 2019 issue, alongside trends mentioned around site practices during the year.

Interest in benchmark data on the scope, performance, and economics of rare disease drug development efforts has grown.

Organizations that continue to disregard the technological needs of one of the industry’s core audiences run the risk of having their trials ignored.

Dr. Daniel Alkon, President & Chief Science Officer at Neurotrope, discusses novel approaches to AD therapy development and why his company chose to target patients with advanced AD for their own.

Global experts collaborate to form the Addressing Lupus Pillars for Health Advancement (ALPHA) Project in order to combat challenges in lupus drug development.

CEO of eXIthera, Neil Hayward, talks about his experience overcoming the challenges of starting up an emerging biopharmaceutical company, including the challenges of preclinical and early-stage development.

Benjamin Hughes, SVP of AI and Real-World Data at IQVIA, discusses how AI is changing the clinical trial paradigm, and how the technologies IQVIA is developing are different from other tech companies that specialize in AI/ML

The latest happenings in the clinical trials world, all in one place.

Krishnan Nandabalan, CEO of InveniAI, discusses how artificial intelligence is shifting the clinical trial paradigm in studies for areas like oncology and the central nervous system.

Irfan Khan, writes that though we celebrate MyStudies' teams work, the FDA’s Patient Engagement Advisory Council deserves specific credit for bringing the patient voice into the design thinking for technologies in clinical research.